Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-4233
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow ; volume:29 ; number:3 ; day:13 ; month:1 ; year:2022 ; pages:487-497 ; date:5.2022
Breast cancer ; 29, Heft 3 (13.1.2022), 487-497, 5.2022
- Creator
-
Grüntkemeier, Lisa
Khurana, Aditi
Bischoff, Farideh Zamaniyan
Hoffmann, Oliver
Kimmig, Rainer
Moore, Mathew
Cotter, Philip
Kasimir-Bauer, Sabine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-022-01330-8
- URN
-
urn:nbn:de:101:1-2022070309015882188253
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Grüntkemeier, Lisa
- Khurana, Aditi
- Bischoff, Farideh Zamaniyan
- Hoffmann, Oliver
- Kimmig, Rainer
- Moore, Mathew
- Cotter, Philip
- Kasimir-Bauer, Sabine
- SpringerLink (Online service)
Other Objects (12)
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer